Novartis v. Cipla: Nilotinib TASIGNA® Patent Suit Dismissed in 18 Days
Novartis AG filed suit against Cipla Limited in the Delaware District Court asserting US8389537B2 over generic nilotinib d-tartrate capsules referencing TASIGNA®. The case was voluntarily dismissed without prejudice just 18 days after filing — a timeline that suggests strategic recalibration rather than a merits resolution.
TASIGNA® Generic Challenge Ended Before It Began
On 21 February 2025, Novartis AG and Novartis Pharmaceuticals Corporation filed suit against Cipla Limited in the U.S. District Court for the District of Delaware before Judge Gregory B. Williams. The complaint asserted U.S. Patent No. 8,389,537 B2, which covers nilotinib d-tartrate capsule formulations, against Cipla’s ANDA filing targeting TASIGNA® capsules in 50 mg, 150 mg, and 200 mg strengths. Nilotinib is a BCR-ABL tyrosine kinase inhibitor approved for chronic myeloid leukaemia, making TASIGNA® a high-value oncology franchise for Novartis.
On 11 March 2025 — just 18 days after filing — Novartis voluntarily dismissed all claims without prejudice under Federal Rule of Civil Procedure 41(a)(1)(A)(i). This procedural mechanism allows a plaintiff to withdraw before the defendant has served an answer or filed a motion for summary judgment, requiring no court order and carrying no cost award against the dismissing party. Crucially, dismissal without prejudice means Novartis has not relinquished its right to reassert the same patent claims against Cipla in a future action.
An 18-day lifecycle is extremely compressed even by the standards of early ANDA dismissals. The public record is silent on whether the parties reached a confidential settlement, Cipla withdrew its ANDA, or Novartis identified a strategic reason to pause litigation. The absence of defendant counsel on the docket and the Rule 41(a)(1)(A)(i) timing — before any responsive pleading — suggests Novartis moved unilaterally, which is consistent with a licensing discussion or a reassessment of patent strategy ahead of any 30-month stay negotiation.
Filing to Dismissed without Prejudice in 18 days
18 days — well below the median ANDA litigation duration of 2–3 years
Dismissed without prejudice: what Rule 41 exit means for both parties
Rule 41(a)(1)(A)(i): the no-cost unilateral exit
Federal Rule 41(a)(1)(A)(i) permits a plaintiff to dismiss an action without court order before the defendant serves an answer or summary judgment motion. The effect is immediate and automatic. Because Cipla had not yet filed a responsive pleading, Novartis could exit unilaterally. No prejudice attaches, and no costs are automatically awarded to the defendant — a clean procedural slate.
Pre-answer voluntary dismissalWithout prejudice: the critical distinction from a final exit
A dismissal without prejudice does not resolve the underlying dispute on the merits — it preserves Novartis’s right to refile the same claims in a future action. This contrasts with a dismissal with prejudice, which would bar re-litigation. The public docket is silent on whether a settlement or licensing agreement was reached. Practitioners should not read this as a concession by Novartis or a clearance event for Cipla’s ANDA — the patent cloud over the generic product remains intact.
Refiling right preservedNo judgment entered — Cipla gains no invalidity or non-infringement finding
Cipla received no court ruling in its favour. The dismissal without prejudice means there is no finding of non-infringement or invalidity that Cipla could invoke as a shield in future proceedings. If Cipla proceeds toward commercialising its ANDA product, it does so without having litigated to a protective judgment. Novartis retains all enforcement options under US8389537B2 and can initiate fresh proceedings at any time within the applicable statute of limitations.
No protective ruling for CiplaTASIGNA® generic entry remains legally uncertain
The unresolved status of US8389537B2 means the commercial pathway for generic nilotinib d-tartrate capsules remains under a patent overhang. Other ANDA filers targeting TASIGNA® should monitor whether Novartis refiles against Cipla or extends enforcement to additional generic applicants. In high-value oncology franchises, strategic dismissals without prejudice sometimes precede broader litigation campaigns or licensing resolutions that restructure the generic entry timeline.
Patent overhang on nilotinib genericsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Novartis, AG | Company | Multinational pharmaceutical company — holder of US8389537B2 covering nilotinib d-tartrateSearch in Eureka ↗ |
| Defendant | Cipla Limited | Individual | Cipla Limited — Indian generic pharmaceutical manufacturer with U.S. ANDA pipelineSearch in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff law firm | McCarter & English LLP | Law Firm | Representing Novartis, AGSearch in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) by its full citation, confirming this was a unilateral plaintiff action requiring no court order or defendant consent. The explicit ‘without prejudice’ language is legally operative: it forecloses any argument by Cipla that the claims are extinguished. The phrasing ‘all claims in the above-captioned action’ indicates a complete rather than partial withdrawal — no residual counts remain pending. No merits finding was reached.
US8389537B2 — nilotinib d-tartrate capsule formulations
U.S. Patent No. 8,389,537 B2 (application no. US13/419132) covers nilotinib d-tartrate capsule formulations — the salt form and dosage technology underpinning TASIGNA® capsules at 50 mg, 150 mg, and 200 mg strengths. Nilotinib is a second-generation BCR-ABL tyrosine kinase inhibitor used in the treatment of chronic myeloid leukaemia. The ‘537 patent’s focus on the d-tartrate salt form suggests it protects formulation-level innovations distinct from the nilotinib compound itself, potentially extending the commercial protection timeline beyond the base compound patent.
TASIGNA® is one of Novartis’s key oncology products, and formulation patents like the ‘537 are a standard second-line defence against generic entry once compound patents expire. For generic manufacturers, the d-tartrate salt claim scope is critical: if the claim covers a specific polymorphic or salt form required for bioequivalence, designing around it without affecting absorption or stability may be technically challenging. Other ANDA applicants for nilotinib d-tartrate products should treat this patent as a primary clearance target given Novartis’s demonstrated willingness to enforce it.
Should you run an FTO against US8389537B2 before entering the nilotinib market?
Any company with an active or pending ANDA for nilotinib d-tartrate capsules — particularly in 50 mg, 150 mg, or 200 mg strengths — faces direct exposure to US8389537B2. Novartis’s decision to file and then dismiss without prejudice confirms the patent is actively managed. R&D and regulatory teams working on nilotinib generics or alternative salt-form formulations should prioritise FTO clearance before incurring further development cost or seeking FDA approval.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US8389537B2 against your formulation parameters, identify relevant prior art that could support an invalidity argument, and surface related Novartis continuation applications that may present additional risk. Given the absence of any invalidity finding in the Cipla case, an independent FTO is the only reliable basis for a clearance opinion on this patent.
Run a freedom-to-operate analysis on US8389537B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: nilotinib & oncology formulation disputes
Explore related Hatch-Waxman patent infringement cases in the Delaware District Court involving oncology formulation patents and ANDA generic entry challenges.
What this case signals for the ANDA oncology IP landscape
An 18-day dismissal without prejudice in a high-stakes oncology ANDA case typically signals more than a simple procedural error.
Pre-answer dismissals in ANDA cases warrant immediate monitoring
When an innovator dismisses an ANDA suit within weeks of filing — before any responsive pleading — it rarely means the dispute is resolved. It more commonly signals a licensing negotiation, an ANDA amendment, or a strategic reset. Companies tracking nilotinib market entry should monitor Delaware dockets for a refiling and the FDA ANDA tracker for Cipla’s application status.
US8389537B2 remains a live enforcement risk for all ANDA filers
The dismissal without prejudice leaves US8389537B2 fully enforceable. Any generic manufacturer with an approved or pending ANDA for nilotinib d-tartrate capsules should conduct a current freedom-to-operate analysis against this patent. The ‘537 patent has not been adjudicated invalid or not infringed — it is an active litigation asset in Novartis’s portfolio.
Novartis v Cipla — key questions answered
The dismissal without prejudice means no court found US8389537B2 invalid or not infringed. Novartis retains the right to refile the same claims. Cipla and any other ANDA applicant for nilotinib d-tartrate capsules cannot rely on this outcome as a clearance event — the patent remains a live enforcement risk.
The public record does not disclose the reason. The compressed timeline and pre-answer filing of the Rule 41(a)(1)(A)(i) notice — before Cipla even entered counsel — is consistent with a confidential licensing or settlement discussion, a Cipla ANDA amendment, or a Novartis strategic reassessment of its Hatch-Waxman litigation posture. No merits ruling was issued.
US8389537B2 (application no. US13/419132) covers nilotinib d-tartrate capsule formulations. It protects the specific salt form and dosage technology used in TASIGNA® 50 mg, 150 mg, and 200 mg capsules. It is a formulation-level patent asserted by Novartis under the Hatch-Waxman Act against Cipla’s ANDA referencing TASIGNA®.
Yes. A Rule 41(a)(1)(A)(i) dismissal without prejudice is not a final judgment on the merits. Novartis can reassert the same claims under US8389537B2 against Cipla in a new action, subject to applicable statutes of limitations and patent term. The dismissal carries no res judicata or collateral estoppel effect.
The case (1:25-cv-00216) was filed in the U.S. District Court for the District of Delaware and assigned to Judge Gregory B. Williams. Novartis was represented by McCarter & English LLP, with Alexandra M. Joyce and Daniel M. Silver as counsel of record. The case closed on 11 March 2025 before any defendant counsel appeared on the docket.
PatSnap Eureka searches patents and litigation data to answer instantly.